rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Transcat, Inc.

TRNS · Nasdaq

Health CareLife-science toolsJust dropped out

TRNS stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 4.2% below that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just dropped out
Weeks in an uptrend
out for 1
Industry in uptrend
54% +4 in 4 wk
Insider buys, 12 months
$197K
Insider sales, 12 months
$1.3M
Officials’ trades on record
0
Institutions holding
164 (+13)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

20 Apr – 19 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.2M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 2
WhoDidSharesTraded
Oksana S. DominachDirectorsold7,312at $85.602 Sep 2026filed 3 Sep 2026
Christopher P. GilletteDirectorsold504at $94.237 Aug 2026filed 12 Aug 2026
Craig D. CairnsDirectorbought1,050at $93.976 Aug 2026filed 10 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders164+13 on the quarter
New · exited34 · 20
Reported value$850.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
NEUBERGER BERMAN GROUP LLCreduced · filed 13 Aug 2026777,366$72.1M-48,372−5.9%
BlackRock, Inc.added · filed 7 Aug 2026727,010$67.4M+52,095+7.7%
Hood River Capital Management LLCreduced · filed 14 Aug 2026601,541$55.8M-13,013−2.1%
Ophir Asset Management Pty Ltdreduced · filed 14 Aug 2026462,016$42.9M-83,499−15.3%
Conestoga Capital Advisors, LLCreduced · filed 24 Jul 2026449,557$41.7M-62,961−12.3%
ROYCE & ASSOCIATES LPreduced · filed 14 Aug 2026431,671$40.0M-182,582−29.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026414,057$38.4M+6,896+1.7%
BARROW HANLEY MEWHINNEY & STRAUSS LLCadded · filed 12 Aug 2026399,983$37.1M+72,541+22.2%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026317,015$29.4M+19,287+6.5%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026275,296$25.5M+13,263+5.1%
31 Mar 2023 – 30 Jun 2026
88125161Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Christopher P. Gillette Company insiderDirector · last 10 Sep 20260 · 2
Craig D. Cairns Company insiderDirector · last 10 Sep 20265 · 0
Cynthia Langston Company insiderDirector · last 10 Sep 20260 · 0
Dawn DePerrior Company insiderDirector · last 10 Sep 20260 · 0
Gary J. Haseley Company insiderDirector · last 10 Sep 20269 · 0
Mbago M. Kaniki Company insiderDirector · last 10 Sep 20260 · 0
Oksana S. Dominach Company insiderDirector · last 10 Sep 20260 · 1
Robert Mecca Company insiderDirector · last 10 Sep 20260 · 0
Royal Thomas Simmons Jr. Company insiderChief Strat. & CorpDev Officer · last 22 Jun 20260 · 0
Jaime A. Irick Company insiderPresident and CEO · last 27 May 20260 · 0
Kristina L. Johnston Company insiderPrincipal Accounting Officer · last 27 May 20260 · 0
Michael Jacques Haddad Company insiderChief Information Officer · last 27 May 20260 · 0

Same industry

OABI OmniAbLeading+67%
TXG 10x GenomicsLeading+59%
AVTR AvantorLeading+45%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+35%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2026 · to 28 Mar 202632.6%
Operating profit marginFY 2026 · to 28 Mar 20264.0%
Free cash flow marginFY 2026 · to 28 Mar 20265.9%
Return on capital employedFY 2026 · to 28 Mar 20263.0%
Cash conversionFY 2026 · to 28 Mar 2026648%
Debt to equityFY 2026 · to 28 Mar 20260.33×
Share count trendFY 2026 · to 22 May 20260.1%
Cash and equivalentsFY 2026 · to 28 Mar 2026$4.9M
Free cash flowFY 2026 · to 28 Mar 2026$19.6M

Analyst forecasts

No analyst forecasts yet.